Senior Manager, HOCT, BD Analytics at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

$150,000 – $220,000Compensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Candidates should possess 4+ years of experience in forecasting, financial modeling, valuation, and/or decision analysis, preferably within the pharmaceutical industry. A graduate degree in a quantitative discipline with significant training in Finance, Management Science, or Decision Analysis is strongly preferred. Demonstrated expertise in structuring and completing insightful financial analyses, coupled with the ability to clearly communicate these insights to senior management, is required. Experience in business development and commercial valuation is preferred, along with a demonstrated ability to manage competing priorities and strong financial valuation modeling and analysis capabilities using spreadsheet software.

Responsibilities

The Senior Manager will act as a key internal consultant, conducting financial analysis of business development opportunities and providing valuation insights for deals to enable value-driven R&D and M&A decisions. They will lead and facilitate product development teams in identifying development strategies, performing financial analysis of development options, and communicating findings to senior management. The role involves integrating other analytic services to ensure development teams leverage BMS's full analytics capabilities, quantifying technical and regulatory risks, and integrating these assessments with projections to value R&D investments. Responsibilities also include supporting the evaluation of licensing and business development opportunities and staying current with advances in decision analysis and risk assessment.

Skills

Financial Analysis

Forecasting

Decision Analysis

Risk Assessment

Statistics

Business Development

Pharmaceutical Industry

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free